Skip to content
MARKETS / NASDAQ / COSM
NASDAQ · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP

Cosmos Health Inc. COSM

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$65.3M
▲ 19.9% YoY
$-19.1M
$-8.5M
In brief

What this company does

We operate in the healthcare sector and particularly in the Pharmaceutical and Nutraceutical businesses. More specifically, we operate in generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services. Through our subsidiaries, we primarily sell pharmaceutical products directly to pharmacies and a limited number of large wholesale drug distributors who, in turn, supply-sell the products to other wholesalers, hospitals, pharmacies, and governmental agencies across the European Union member state. As of December 31, 2025, we had a total of 163 full-time employees.

Written from the business description in Cosmos Health Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
USD 65.3M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 65.3 · Net income -19.1
25.0M50.0M-8.0M-16.0M201020122014201620182020202220242025
Compound annual growth
+9.0%
+3.3%
+61.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -25.6% · Net -29.3%
-500%-1000%201020122014201620182020202220242025
ROE
FY2025 · ROE -89.1%
-2000%-4000%-6000%201020122014201620182020202220242025

Each USD of equity lost 89 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.5
2.5M5.0M-8.0M-16.0M201020122014201620182020202220242025
Net buybacks $ Dividends $
FY2024 · Dividends — · Net buybacks -649039.0
200000.0-250000.0-500000.02020202120232024

Total assetsUSD 65.5M
EquityUSD 18.4M
CashUSD 715,674.00
Gross debtUSD 3.8M
Net debtUSD 3.1M
Current ratio1.00×

Net debt stands at 17% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.10.10.10.00.00.00.00.00.00.0···
Operating income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0·
EBITDA $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.00.0····
Income tax $B0.00.00.0−0.00.0−0.00.0−0.00.00.00.00.00.0···
Net income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0·−0.0−0.0−0.0−0.00.0····
EPS, diluted $−0.63−1.17−2.15−33.16−23.740.06−0.25−0.68−0.4980741.00−0.050.050.000.00−0.01·
Dividend / sh $················
Payout %················
ROE %−89.1−53.4−49.2−63.3−7289.2·····−316.5223.1····
Shares out B0.040.020.020.010.000.010.010.010.010.010.130.130.130.100.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 1 failures in 69 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image